Leerink Partners analyst David Risinger has maintained their bullish stance on REGN stock, giving a Buy rating on April 11.
David Risinger has given his Buy rating due to a combination of factors impacting Regeneron’s stock. Despite the temporary closure of the Good Days Foundation, which affected the sales of Eylea, Regeneron’s revenue and earnings projections remain strong. Risinger notes that while the closure of the foundation has led to some patient treatment interruptions, Regeneron’s financial outlook is still positive, with expected revenues aligning with consensus estimates and earnings slightly above expectations.
Furthermore, the importance of foundation support is highlighted, as it plays a crucial role in patient access to therapy, especially for Medicare recipients. Although the Good Days Foundation was closed for a significant period, Regeneron has shown resilience and adaptability in managing these challenges. Risinger maintains an optimistic outlook for Regeneron’s shares, considering the company’s ability to navigate these temporary setbacks effectively.
In another report released on April 11, Goldman Sachs also maintained a Buy rating on the stock with a $917.00 price target.
REGN’s price has also changed dramatically for the past six months – from $1014.250 to $571.060, which is a -43.70% drop .